Research programme: controlled-release sartan - Allist PharmaceuticalsAlternative Names: Controlled onset extended release sartan; Controlled-onset releasing sartan; Time controlled release sartan
Latest Information Update: 16 Jul 2016
At a glance
- Originator Allist Pharmaceuticals
- Mechanism of Action Angiotensin receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hypertension in China (PO)